{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DRTS",
  "name": "Alpha Tau Medical Ltd.",
  "url": "https://frontierpicks.com/dossiers/DRTS/",
  "json_url": "https://frontierpicks.com/dossiers/DRTS.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Head-and-neck re-acceleration: a 2026-06-23 first-ex-US glioblastoma treatment drove a +17.9% breakout to new 52-week highs (~$12.56 on 7/11), reclaiming the $11.99 Tolmar equity shelf. The 2026-07-21 AHNS podium with complete Alpha DaRT + pembrolizumab HNSCC top-line is the dated binary that extends or breaks the leg.",
  "invalidation_trigger": "A daily close below $11.60 relinquishes the reclaimed breakout shelf (the prior 52-week high and the $11.99 Tolmar equity strike) and points back toward the ~$8.95 pre-deal base; a soft or negative 2026-07-21 AHNS head-and-neck top-line read is the secondary thesis-break.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-06-11",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology",
    "medtech-diagnostics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue device developer with no US-approved product; the valuation rests on trial and regulatory progress rather than sales.",
    "Modular PMA means FDA progress arrives in fragments (module submissions, review feedback) rather than one PDUFA-style dated decision.",
    "US-listed Israeli-domiciled issuer; quarterly results are released before the US open, so reactions gap at the open rather than in after-hours trade.",
    "TASE dual listing registered 2026-08-10 covering 146M+ ordinary shares incl. option/warrant underliers; once trading starts, Israeli-session pricing precedes the US open.",
    "Average daily volume near 1M shares — single clinical headlines have produced double-digit percentage sessions in both directions."
  ],
  "body_markdown": "## Current Thesis\nThe catalyst gap flagged in the prior note closed faster than expected, and it closed upward. On 2026-08-10 Alpha Tau reported Q2 with $104.8M in cash, equivalents and deposits at 2026-06-30 (versus $76.9M at 2025-12-31), disclosed the first interim readout from REGAIN in recurrent glioblastoma, and registered for a dual listing on the Tel Aviv Stock Exchange. HC Wainwright raised its target to $16 from $15 on 2026-08-11. The adjusted daily series puts the 2026-08-21 close at $14.92, which is the 52-week high itself, up 48.6% over three months with RSI(14) at 78.5. The leg an investor is buying is the platform re-rating: Alpha DaRT moving from one pivotal skin-cancer trial to a multi-indication file — cSCC (ReSTART, 88 patients enrolled), glioblastoma (REGAIN), pancreatic (IMPACT) — funded past the readout and with a US commercial partner already on the cap table. What is missing is timing. The 2026-08-10 update guided ReSTART top-line to \"late 2026 or early 2027\", a widening from the earlier late-H2-2026 language, so the registrational datapoint that actually validates the modular PMA is not inside this quarter. The narrative is **accelerating** — dated by the 2026-08-21 new high, the 2026-08-11 target raise and the fresh 2026-08-10 REGAIN and TASE headlines — but accelerating from an extended price with no registrational event in the next 30 days.\n\n## Bull Case\n- **Balance sheet is no longer the constraint.** Cash, equivalents, short-term and restricted deposits of $104.8M at 2026-06-30 against $76.9M at 2025-12-31 (Q2 2026 results, 2026-08-10). The build spans the ~$35M Tolmar upfront announced 2026-06-03. Six-month R&D of $20.9M versus $14.2M a year earlier shows the spend going into trials rather than overhead.\n- **A second indication produced data, not just enrollment.** REGAIN recurrent glioblastoma interim, disclosed 2026-08-10: first three patients, 100% local disease control, 67% complete response (two CRs, one stable disease with 30% tumour reduction), one grade 3 serious adverse event that resolved with steroids. Three patients is a signal of feasibility, not efficacy — but it is a new indication with a live dataset.\n- **The pivotal is fully enrolled and the regulatory file is open.** ReSTART US multi-centre pivotal in recurrent cSCC enrolled 88 patients (enrollment completed 2026-05-08); the first module of the modular PMA went to FDA in January 2026. Approval risk remains, but the submission machinery is running.\n- **Sell-side moved up after the miss, not down.** HC Wainwright maintained Buy and raised the target to $16 on 2026-08-11, the session after a headline EPS miss — the analyst response keyed off cash and pipeline rather than the loss line.\n- **The shareholder base is being widened by design.** TASE dual-listing registration on 2026-08-10 covers more than 146 million ordinary shares including those underlying options, warrants and employee plans, under English ticker DRTS. Israeli institutional access is a distribution channel a US-only micro cap does not have.\n\n## Bear Case\n- **The loss line is ugly and unreconciled.** The company release reports a Q2 2026 net loss of $68.8M, or $0.76 per share, against $18.8M ($0.25) in Q2 2025. Benzinga's 2026-08-10 earnings item recorded EPS of -$0.50 versus a -$0.14 consensus. Cash rose over the same six months, which implies a large non-cash component, but nothing in the material cited here itemizes it — a reader should treat the quarter's true operating burn as unresolved until the 6-K detail is read.\n- **The registrational date got looser, not tighter.** \"Late 2026 or early 2027\" (2026-08-10) replaces the previous late-H2-2026 framing. The prior note listed exactly this — a Q2 update pushing ReSTART into 2027 — as the observable for catalyst-gap risk. It half-triggered, and the stock made new highs anyway.\n- **Three patients is three patients.** The REGAIN interim and the July HNSCC combination result (100% ORR across nine evaluable patients, 18.2-month median OS, 2026-07-21) are both small, single-arm and selected. Neither de-risks the cSCC primary endpoint.\n- **Insider supply stepped up with the price.** CFO Raphi Levy sold 17,730 shares at an average of $14.00 on 2026-08-11 under a Rule 10b5-1 plan, leaving 90,180 shares directly held. The plan is pre-arranged, so this is not a discretionary read on value — but the size is roughly eight times the July cadence and it printed into the high.\n- **Still pre-revenue.** No US-approved product; consensus revenue for the quarter was in the low hundreds of thousands of dollars. Every dollar of the market cap is trial and regulatory progress.\n\n## Setup & Price Structure\nThe 2026-08-21 close of $14.92 is the 52-week high, 0.0% below it, after a three-month advance of 48.6%. RSI(14) at 78.5 is the highest reading in the covered period — the 2026-08-07 close of $13.14 carried RSI 47.0 with price 3.2% under the then-high of $13.57. The Q2 print therefore did two things at once: it broke a two-week range and it consumed most of the distance to the only current published target, HC Wainwright's $16 (2026-08-11). Crowding observables, stated plainly: price at the high with RSI 78.5; a three-month move of +48.6%; an officer selling roughly eight times his July size on 2026-08-11; a registration statement covering 146M+ shares including option and warrant underliers; average daily volume near 1M shares, which is why single clinical headlines have produced double-digit sessions in both directions. There is no earnings date inside the next 30 days to force a resolution.\n\n## Catalyst Calendar (next 30 days)\n\n- **Nothing confirmed with a fixed date before 2026-09-21.** The Q2 print (2026-08-10) is spent and Q3 results are not scheduled; the Q1/Q2 cadence (2026-05-18, 2026-08-10) points to mid-November.\n- **~2026-09-30 (est.)** — IMPACT pancreatic trial recruitment completion, guided to Q3 2026 in the 2026-08-10 corporate update. A completion announcement is the only company-guided item that could land near the window's edge.\n- **~2026-12-31 (est.)** — REGAIN glioblastoma enrollment completion guided to H2 2026 with data expected by year-end.\n- **~2026-12-31 to ~2027-03-31 (est.)** — ReSTART pivotal cSCC top-line, guided 2026-08-10 to \"late 2026 or early 2027\".\n\n## Elapsed catalysts\n\n- **TASE trading commencement, date not fixed** — registration was announced 2026-08-10; the start of Israeli-session trading has not been dated publicly. *(passed 16d ago)*\n\n## What Would Change Our Mind\nThe structure that has to hold is the post-Q2 breakout over the prior $13.57 high; losing it means the 2026-08-10 package (cash, REGAIN interim, TASE) was a one-print repricing rather than the start of a platform re-rating. Concretely, a daily close below $13.50 gives that shelf back and puts the $11.99 Tolmar strike back in play as the next reference. Three non-price conditions would independently break the frame: a Q3 update (est. mid-November) that moves ReSTART top-line past Q1 2027 or removes the date entirely; an ATM programme, registered direct or shelf takedown disclosed in a 6-K, which would convert the TASE registration's 146M-share coverage from access into supply; or REGAIN's enrollment-complete dataset showing a complete-response rate materially below the 67% seen in the first three patients. On the upside, the label would firm rather than flip if ReSTART top-line were fixed to a specific date and a second broker initiated with published estimates — analyst coverage is currently thin enough that one voice sets the target.\n\n## Correlation Notes\n- Clinical-stage micro-cap medtech with no revenue trades on small-cap biotech risk appetite; XBI drawdowns pull names like this regardless of company news, and the 1M-share average volume amplifies the move.\n- Israeli-domiciled issuer with operations in Israel: regional risk episodes have historically hit Tel Aviv-linked US listings independent of fundamentals. The 2026-08-10 TASE registration increases that linkage once trading begins, since price discovery would start in the Israeli session before the US open.\n- The comparable set is alpha/beta-emitting radiotherapeutics rather than oncology pharma — sentiment in radiopharma peers moves the group's multiple, and read-throughs from any alpha-emitter safety event would be sector-wide.\n- Single-analyst target concentration (HC Wainwright, $16 as of 2026-08-11) means broker actions are idiosyncratic events here, not consensus drift.\n\n## Positioning & Life-Cycle\nThe narrative is **accelerating**, dated by the 2026-08-21 new 52-week high at $14.92, the 2026-08-11 target raise to $16, and the 2026-08-10 cluster of Q2 cash, REGAIN interim and TASE registration. What would date a flip to saturated: retail-sentiment coverage clustering without new company disclosures, further Form 4 sales at or above the 17,730-share size, or a failure to hold $13.57 on the first pullback — the last of which is the same condition as the price break above.",
  "first_seen": "2026-05-20",
  "last_analyzed": "2026-08-22T08:13:13+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}